JP2011504462A - 腫瘍の予防および治療のための方法および化合物 - Google Patents

腫瘍の予防および治療のための方法および化合物 Download PDF

Info

Publication number
JP2011504462A
JP2011504462A JP2010533046A JP2010533046A JP2011504462A JP 2011504462 A JP2011504462 A JP 2011504462A JP 2010533046 A JP2010533046 A JP 2010533046A JP 2010533046 A JP2010533046 A JP 2010533046A JP 2011504462 A JP2011504462 A JP 2011504462A
Authority
JP
Japan
Prior art keywords
histone
cell
protein
tumor
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010533046A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011504462A5 (https=
Inventor
ユイ、チャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science Technology and Research Singapore
Original Assignee
Agency for Science Technology and Research Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science Technology and Research Singapore filed Critical Agency for Science Technology and Research Singapore
Publication of JP2011504462A publication Critical patent/JP2011504462A/ja
Publication of JP2011504462A5 publication Critical patent/JP2011504462A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2010533046A 2007-11-02 2008-11-03 腫瘍の予防および治療のための方法および化合物 Withdrawn JP2011504462A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98483507P 2007-11-02 2007-11-02
US5948208P 2008-06-06 2008-06-06
PCT/SG2008/000420 WO2009058102A1 (en) 2007-11-02 2008-11-03 Methods and compounds for preventing and treating a tumour

Publications (2)

Publication Number Publication Date
JP2011504462A true JP2011504462A (ja) 2011-02-10
JP2011504462A5 JP2011504462A5 (https=) 2012-01-05

Family

ID=40591309

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010533046A Withdrawn JP2011504462A (ja) 2007-11-02 2008-11-03 腫瘍の予防および治療のための方法および化合物

Country Status (6)

Country Link
US (2) US8969313B2 (https=)
EP (1) EP2217240A4 (https=)
JP (1) JP2011504462A (https=)
CN (1) CN101909630A (https=)
SG (1) SG185942A1 (https=)
WO (1) WO2009058102A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019535017A (ja) * 2016-10-06 2019-12-05 ザ・ジョンズ・ホプキンス・ユニバーシティ ラージスケールエピゲノムのリプログラミングは、膵癌進行の進展中の同化グルコース代謝を遠位転移に結びつける

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110189097A1 (en) * 2009-11-09 2011-08-04 Dritan Agalliu Use of WNT inhibitor to inhibit angiogenesis in the CNS
EP2569625A4 (en) * 2010-05-11 2013-12-04 Ann And Robert H Lurie Children S Hospital Of Chicago METHOD FOR DETECTING AND PROFILING THE PROGRESS OF THE RISK OF A NEURODEEGENERATIVE DISEASE
EP2666020A1 (en) * 2011-01-18 2013-11-27 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods for amplification and detection of prions
US9090944B2 (en) 2011-12-16 2015-07-28 The Chinese University Of Hong Kong Biomarker DACT1 for gastric cancer
GB201309333D0 (en) 2013-05-23 2013-07-10 Agency Science Tech & Res Purine diones as WNT pathway modulators
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
CN105567797A (zh) * 2014-11-11 2016-05-11 香港中文大学深圳研究院 检测DACT2基因启动子区CpG岛甲基化的PCR引物、方法和试剂盒
WO2017019721A2 (en) * 2015-07-28 2017-02-02 Constellation Pharmaceuticals, Inc. Combination therapies for modulation of histone methyl modifying enzymes
US10577350B2 (en) 2015-08-28 2020-03-03 Constellation Pharmaceuticals, Inc. Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
GB201516972D0 (en) * 2015-09-25 2015-11-11 Epiontis Gmbh LRP5 as epigenetic marker for the identification of immune cells, in particular B-cells
FR3042202B1 (fr) * 2015-10-13 2020-02-07 Institut National De La Recherche Agronomique Procede de criblage de composes a effet anti-inflammatoire base sur la proteine dact3 et nouvelles strategies therapeutiques
US10765471B2 (en) 2016-04-15 2020-09-08 Bolder Surgical, Llc Electrosurgical sealer and divider
US20180139464A1 (en) * 2016-11-17 2018-05-17 Mediatek Inc. Decoding system for tile-based videos
CN110408688B (zh) * 2019-05-22 2023-05-02 中山大学附属第一医院 Dact1基因在制备房颤诊断和治疗产品中的应用
CN111802326B (zh) * 2020-07-09 2022-06-17 中山大学附属口腔医院 一种Kras突变相关口腔黏膜恶变动物模型的构建方法
CN114994323B (zh) * 2021-02-20 2024-12-24 中国医学科学院基础医学研究所 IgG Fc N-糖肽作为确定或辅助肺癌治疗方案选择的标志物的用途
CN114561466B (zh) * 2022-01-25 2023-06-13 中山大学附属第一医院 Fto在诊治骨肉瘤中的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57102889A (en) 1980-12-19 1982-06-26 Toyo Jozo Co Ltd 2'-(r)-substituted-2'-deoxyneplanocin a derivative
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
JPH02215781A (ja) 1989-02-14 1990-08-28 Toyo Jozo Co Ltd ６’―デオキシ―６’―ハロゲノネプラノシンａおよびその製造法
DE69105495T2 (de) 1990-04-02 1995-04-06 Pfizer Benzylphosphonsäure-tyrosinkinaseinhibitoren.
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
US5409930A (en) 1991-05-10 1995-04-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
EP0586608A1 (en) 1991-05-29 1994-03-16 Pfizer Inc. Tricyclic polyhydroxylic tyrosine kinase inhibitors
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
WO1994003427A1 (en) 1992-08-06 1994-02-17 Warner-Lambert Company 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and which have antitumor properties
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
AU5132096A (en) 1995-01-30 1996-08-21 Terrapin Technologies, Inc. Glubodies - multiplicities of proteins capable of binding a variety of small molecules
JP2002507404A (ja) 1998-03-27 2002-03-12 ジェネンテク・インコーポレイテッド Ａｐｏ−２リガンド−抗ＨＥＲ−２抗体相乗作用
SE517975C2 (sv) 2000-05-30 2002-08-13 Power Ab C Fackverkskonstruktion av balkar sammansatta till ett tredimensionellt ramverk samt användning av en sådan fackverkskonstruktion
KR20090089922A (ko) * 2000-10-18 2009-08-24 파마셋 인코포레이티드 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드
US20050191618A1 (en) 2001-05-18 2005-09-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
US7691970B2 (en) 2003-08-25 2010-04-06 Pieris Ag Muteins of a bilin-binding protein with affinity for a given target
US20050245559A1 (en) 2004-01-23 2005-11-03 Koul Hari K Treatment and prevention of prostate cancer
WO2005105136A1 (en) 2004-04-27 2005-11-10 University Of South Florida Nanogene therapy for cell proliferation disorders
ATE511859T1 (de) 2004-07-20 2011-06-15 Schering Corp Apoptoseinduktion in toll-artige rezeptoren exprimierenden tumorzellen
JP2009514891A (ja) * 2005-11-04 2009-04-09 メルク エンド カムパニー インコーポレーテッド 癌を治療するためのｓａｈａ及びエルロチニブを用いる方法
AU2006339445A1 (en) 2006-03-02 2007-09-07 Agency For Science, Technology And Research Methods for cancer therapy and stem cell modulation
EP2144606A2 (en) 2007-04-05 2010-01-20 Max-Delbrück-Centrum Für Molekulare Medizin Remedy for the treatment of cardio-vascular diseases or disorders

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019535017A (ja) * 2016-10-06 2019-12-05 ザ・ジョンズ・ホプキンス・ユニバーシティ ラージスケールエピゲノムのリプログラミングは、膵癌進行の進展中の同化グルコース代謝を遠位転移に結びつける
JP7239468B2 (ja) 2016-10-06 2023-03-14 ザ・ジョンズ・ホプキンス・ユニバーシティ ラージスケールエピゲノムのリプログラミングは、膵癌進行の進展中の同化グルコース代謝を遠位転移に結びつける
US11795510B2 (en) 2016-10-06 2023-10-24 The Johns Hopkins University Identification of epigenomic reprogramming in cancer and uses thereof

Also Published As

Publication number Publication date
US8969313B2 (en) 2015-03-03
CN101909630A (zh) 2010-12-08
US20160015693A1 (en) 2016-01-21
EP2217240A1 (en) 2010-08-18
WO2009058102A1 (en) 2009-05-07
EP2217240A4 (en) 2012-09-12
US20110053882A1 (en) 2011-03-03
SG185942A1 (en) 2012-12-28

Similar Documents

Publication Publication Date Title
US8969313B2 (en) Methods and compounds for preventing and treating a tumour
Zhao et al. Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer
Peng et al. Role of FAT1 in health and disease
Song et al. Cdc2-like kinases: structure, biological function and therapeutic targets for diseases
Gao et al. Long noncoding RNA URB1-antisense RNA 1 (AS1) suppresses sorafenib-induced ferroptosis in hepatocellular carcinoma by driving ferritin phase separation
Iannelli et al. Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition
Li et al. Inactivation of SAG/RBX2 E3 ubiquitin ligase suppresses Kras G12D-driven lung tumorigenesis
López‐Hernández et al. The endoplasmic reticulum stress and the HIF‐1 signalling pathways are involved in the neuronal damage caused by chemical hypoxia
Covey et al. PORCN moonlights in a Wnt-independent pathway that regulates cancer cell proliferation
Yu et al. Natural HDAC‐1/8 inhibitor baicalein exerts therapeutic effect in CBF‐AML
Al Labban et al. Notch-effector CSL promotes squamous cell carcinoma by repressing histone demethylase KDM6B
WO2014074805A1 (en) Selective targeting of cancer stem cells
Hembram et al. Quinacrine based gold hybrid nanoparticles caused apoptosis through modulating replication fork in oral cancer stem cells
US20240398804A1 (en) Methods of treating cancer having an active wnt/beta-catenin pathway
Lou et al. Insight into the physiological and pathological roles of USP44, a potential tumor target
Wang et al. Chlorquinaldol targets the β-catenin and T-cell factor 4 complex and exerts anti-colorectal cancer activity
Lu et al. Differential regulation of CDX1 and CDX2 gene expression by deficiency in methyl group donors
CA2651555A1 (en) Methods and compositions related to tr4
Elkabets et al. Pharmacological activation of SIRT6 suppresses progression of head and neck and esophagus squamous cell carcinoma by modulation of cellular metabolism and protein translation
US20250146080A1 (en) Methods for overcoming tazemetostat-resistance in cancer patients
US9316631B1 (en) ER-stress inducing compounds and methods of use thereof
WO2014186573A2 (en) Use of sumoylation inhibitors for treating cancer
Costa Dissecting the role of G9a/GLP histone methyltransferases in Platinum-resistant ovarian cancer
Menegazzi ELUCIDATING THE ROLE OF PROMYELOCYTIC LEUKEMIA GENE IN CLEAR CELL RENAL CELL CARCINOMA
Mannino Antitumor effect of SOS-1/KRAS inhibitor BAY-293 against head and neck carcinoma

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111102

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111102

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20120120

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20130117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130117